Cargando…
Efficiency and safety of subconjunctival injection of anti-VEGF agent – bevacizumab – in treating dry eye
PURPOSE: Dry eye is a chronic inflammatory ocular surface disease with high prevalence. The current therapies for dry eye remain to be unspecific and notcomprehensive. This study aims to explore safety and efficacy of a novel treatment – subconjunctival injection of bevacizumab – in dry eye patients...
Autores principales: | Jiang, Xiaodan, Lv, Huibin, Qiu, Weiqiang, Liu, Ziyuan, Li, Xuemin, Wang, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472070/ https://www.ncbi.nlm.nih.gov/pubmed/26109847 http://dx.doi.org/10.2147/DDDT.S85529 |
Ejemplares similares
-
Efficacy of intra-meibomian gland injection of the anti-VEGF agent bevacizumab for the treatment of meibomian gland dysfunction with lid-margin vascularity
por: Jiang, Xiaodan, et al.
Publicado: (2018) -
Regression of Iris Neovascularization after Subconjunctival Injection of Bevacizumab
por: Ryoo, Na Kyung, et al.
Publicado: (2013) -
The efficiency of subconjunctival bevacizumab in refractory glaucoma - case report
por: Popescu, V, et al.
Publicado: (2015) -
Simultaneous Subconjunctival Triamcinolone and Bevacizumab Injections for Management of Blepharokeratoconjunctivitis in Children
por: Nguyen, Chu Luan, et al.
Publicado: (2018) -
Correlation Analysis of Ocular Symptoms and Signs in Patients with Dry Eye
por: Song, Hang, et al.
Publicado: (2017)